Oligo-branched peptides for tumor targeting: From magic bullets to magic forks

Expert Opinion on Biological Therapy

Volumn 9, Issue 2, 2009, Pages 171-178

  Falciani, Chiara ^a   Pini, Alessandro ^a   Bracci, Luisa ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Cancer; Oligo branched peptides; Tumor targeting

Indexed keywords

ANGIOPEPTIN; BOMBESIN DERIVATIVE; BORTEZOMIB; CETUXIMAB; DENDRIMER; GASTRIN RELEASING PEPTIDE; GLUCAGON LIKE PEPTIDE; IMATINIB; MULTIPLE ANTIGEN PEPTIDE; NEUROPEPTIDE Y; NEUROTENSIN; NEUROTENSIN DERIVATIVE; OCTREOTIDE; OLIGOPEPTIDE; PENTETREOTIDE; PEPTIDE; RITUXIMAB; SOMATOSTATIN; SUBSTANCE P; TRASTUZUMAB; UNCLASSIFIED DRUG; VAPREOTIDE;

AMINO ACID SEQUENCE; BIOLOGICAL ACTIVITY; BREAST CANCER; CANCER DIAGNOSIS; CANCER THERAPY; CARDIOTOXICITY; CHEMICAL STRUCTURE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED STUDY; DRUG CONJUGATION; DRUG TARGETING; GASTROINTESTINAL TUMOR; HUMAN; LYMPHOMA; MULTIPLE MYELOMA; NEOPLASM; NONHUMAN; ONCOLOGY; PANCREAS TUMOR; PROTEIN EXPRESSION; REVIEW; PATHOLOGY;

HUMANS; NEOPLASMS; OLIGOPEPTIDES;

EID: 66149107506     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590802620501     Document Type: Review

References (68)

1. Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 2006;6:714-727 (Pubitemid 44286003)
2. Kerkelä R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006;12:908-916 (Pubitemid 44175142)
3. Verweij J, Casali PG, Kotasek D, et al. Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005. Eur J Cancer 2007;43:974-978 (Pubitemid 46505099)
4. Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 2006;2:147-159
5. Ricart A, Tolcher AW. Technology insight: cytotoxic drug immunoconjugates for cancer therapy. Nat Clin Pract Oncol 2007;4:245-255 (Pubitemid 46510534)
6. Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy. Cancer J 2008;14:154-169
7. Schally AV. Oncological applications of somatostatin analogues. Cancer Res 1988;48:6977-6985 (Pubitemid 19013968)
8. Krenning EP, Bakker WH, Breeman WA, et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1989;1:242-244 (Pubitemid 19045470)
9. Reubi JC. Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. J Nucl Med 1995;36:1825-1835
10. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003;24:389-427 (Pubitemid 37056239)
11. Langer M, Beck-Sickinger AG. Peptides as carriers for tumor diagnosis and treatment. Curr Med Chem Anti-Cancer Agents 2001;1:71-93
12. Available from: www.fda.gov
13. Guillermet-Guibert J, Lahlou H, Pyronnet S, et al. Endocrine tumours of the gastrointestinal tract. Somatostatin receptors as tools for diagnosis and therapy: molecular aspects. Best Pract Res Clin Gastroenterol 2005;19:535-551
14. Reubi JC, Macke HR, Krenning EP. Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 2005;46:S67-75 (Pubitemid 47619021)
15. Faintuch BL, Teodoro R, Duatti A, et al. Radiolabeled bombesin analogs for prostate cancer diagnosis: preclinical studies. Nucl Med Biol 2008;35:401-411 (Pubitemid 351637643)
16. Okarvi SM. Peptide-based radiopharmaceuticals and cytotoxic conjugates: potential tools against cancer. Cancer Treat Rev 2008;34:13-26 (Pubitemid 351168607)
17. Ginj M, Zhang H, Waser B, et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci USA 2006;103:16436-16441 (Pubitemid 44715214)
18. Aina OH, Liu R, Sutcliffe JL, et al. From combinatorial chemistry to cancer-targeting peptides. Mol Pharm 2007;4:631-651 (Pubitemid 350004263)
19. Tam JP. Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc Natl Acad Sci USA 1988;85:5409-5413 (Pubitemid 18207061)
20. Sadler K, Tam JP. Peptide dendrimers: applications and synthesis. J Biotechnol 2002;90:195-229 (Pubitemid 34179575)
21. Niederhafner P, Sebestík J, Jezek J. Peptide dendrimers. J Pept Sci 2005;11:757-788 (Pubitemid 43009617)
22. Saravanan P, Kumar S, Kataria JM. Use of multiple antigenic peptides related to antigenic determinants of infectious bursal disease virus (IBDV) for detection of anti-IBDV-specific antibody in ELISA-quantitative comparison with native antigen for their use in serodiagnosis. J Immunol Methods 2004;293:61-70 (Pubitemid 39468332)
23. Ndongmo CB, Switzer WM, Pau CP, et al. New multiple antigenic peptide-based enzyme immunoassay for detection of simian immunodeficiency virus infection in nonhuman primates and humans. J Clin Microbiol 2004;42:5161-5169 (Pubitemid 39506225)
24. Mezo G, de Oliveira E, Krikorian D, et al. Synthesis and comparison of antibody recognition of conjugates containing herpes simplex virus type 1 glycoprotein D epitope VII. Bioconjug Chem 2003;14:1260-1269 (Pubitemid 37449056)
25. Vlachoyiannopoulos PG, Mavragani CP, Bourazopoulou E, et al. Anti-CD40 antibodies in antiphospholipid syndrome and systemic lupus erythematosus. Thromb Haemost 2004;92:1303-1311 (Pubitemid 39642541)
26. Schott ME, Wells DT, Schlom J, et al. Comparison of linear and branched peptide forms (MAPs) in the induction of T helper responses to point-mutated ras immunogens. Cell Immunol 1996;174:199-209 (Pubitemid 26426213)
27. Horváth A, Tóth GK, Gogolák P, et al. A hemagglutinin-based multipeptide construct elicits enhanced protective immune response in mice against influenza A virus infection. Immunol Lett 1998;60:127-136 (Pubitemid 28157256)
28. Taborda CP, Nakaie CR, Cilli EM, et al. Synthesis and immunological activity of a branched peptide carrying the T-cell epitope of gp43, the major exocellular antigen of Paracoccidioides brasiliensis. Scand J Immunol 2004;59:58-65 (Pubitemid 38186840)
29. Edelman R, Wasserman SS, Kublin JG, et al. Immediate-type hypersensitivity and other clinical reactions in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum sporozoites. Vaccine 2002;21:269-280 (Pubitemid 35350854)
30. Kublin JG, Lowitt MH, Hamilton RG, et al. Delayed-type hypersensitivity in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum sporozoites. Vaccine 2002;2:1853-1856 (Pubitemid 34242843)
31. Avila SL, Goldberg AC, Arruk VG, et al. Immune responses to multiple antigen peptides containing T and B epitopes from Plasmodium falciparum circumsporozoite protein of Brazilian individuals naturally exposed to malaria. Parasite Immunol 2001;23:103-108 (Pubitemid 32231912)
32. Mammen M, Choi SK, Whitesides GM. Polyvalent interactions in biological systems: implication for design and use of multivalent ligands and inhibitors. Angew Chem Int Ed 1998;37:2754-2794 (Pubitemid 29008561)
33. Handl HL, Vagner J, Han H, et al. Hitting multiple targets with multimeric ligands. Expert Opin Ther Targets 2004;8:565-586 (Pubitemid 40028367)
34. Kiessling KL, Gestwicki JE, Strong LE. Synthetic multivalent ligands as probes of signal transduction. Angew Chem Int Ed 2006;45:2348-2368 (Pubitemid 44105109)
35. Bracci L, Lozzi L, Pini A, et al. A branched peptide mimotope of the nicotinic receptor binding site is a potent synthetic antidote against the snake neurotoxin α-bungarotoxin. Biochemistry 2002;41:10194-10199 (Pubitemid 34856443)
36. Lozzi L, Lelli B, Runci Y, et al. Rational design and molecular diversity for the construction of anti-α-bungarotoxin antidotes with high affinity and in vivo efficiency. Chem Biol 2003;10:411-417 (Pubitemid 36599249)
37. Bracci L, Falciani C, Lelli B, et al. Synthetic peptides in the form of dendrimers become resistant to protease activity. J Biol Chem 2003;278:46590-46595 (Pubitemid 37452233)
38. Falciani C, Lozzi L, Pini A, et al. Molecular basis of branched peptides resistance to enzyme proteolysis. Chem Biol Drug Des 2007;69:216-221 (Pubitemid 46608454)
39. Falciani C, Lozzi L, Pini A, et al. Bioactive peptides from libraries. Chem Biol 2005;12:417-426 (Pubitemid 40588916)
40. Pini A, Giuliani A, Falciani C, et al. Antimicrobial activity of novel dendrimeric peptides obtained by phage display selection and rational modification. Antimicrob Agents Chemother 2005;49:2665-2672 (Pubitemid 40917576)
41. Pini A, Runci Y, Falciani C, et al. Stable peptide inhibitors prevent binding of lethal and oedema factors to protective antigen and neutralize anthrax toxin in vivo. Biochem J 2006;395:157-163
42. Tam JP, Lu YA, Yang JL. Antimicrobial dendrimeric peptides. Eur J Biochem 2002;269:923-932 (Pubitemid 34175413)
43. Klajnert B, Janiszewska J, Urbanczyk-Lipkowska Z, et al. Biological properties of low molecular mass peptide dendrimers. Int J Pharm 2006;309(17):208-217 (Pubitemid 43129484)
44. Pini A, Falciani C, Bracci L. Branched peptides as therapeutics. Cur Prot Pep Sci 2008;9:468-477
45. Chafekar SM, Malda H, Merkx M, et al. Branched KLVFF tetramers strongly potentiate inhibition of β-amyloid aggregation. Chembiochem 2007;8:1857-1864 (Pubitemid 47612876)
46. 3 expression. Eur J Nucl Med Mol Imaging 2008;35:1100-1108
47. 18F-FPRGD4). J Nucl Med 2007;48:1536-1544
48. 3 integrin expression. J Nucl Med 2007;48:1162-1171
49. Cao Q, Li ZB, Chen K, et al. Evaluation of biodistribution and anti-tumor effect of a dimeric RGD peptide-paclitaxel conjugate in mice with breast cancer. Eur J Nucl Med Mol Imaging 2008;35:1489-1498
50. Vagner J, Xu L, Handl HL, et al. Heterobivalent ligands crosslink multiple cell-surface receptors: the human melanocortin-4 and δ-opioid receptors. Angew Chem Int Ed Engl 2008;47:1685-1688
51. Li ZB, Wu Z, Chen K, et al. 18F-labeled BBN-RGD heterodimer for prostate cancer imaging. J Nucl Med 2008;49:453-461 (Pubitemid 351355212)
52. Boas U, Heegaard PM. Dendrimers in drug research. Chem Soc Rev 2004;10;33:43-63 (Pubitemid 38376610)
53. Lee CC, MacKay JA, Fréchet JM, et al. Designing dendrimers for biological applications. Nat Biotechnol 2005;23:1517-1526 (Pubitemid 41752929)
54. Wolinsky JB, Grinstaff MW. Therapeutic and diagnostic applications of dendrimers for cancer treatment. Adv Drug Deliv Rev 2008;60:1037-1055
55. Carraway R, Leeman SE. The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J Biol Chem 1973;248:6854-6861
56. Reubi JC. Somatostatin and other peptide receptors as tools for tumor diagnosis and treatment. Neuroendocrinology 2004;80:51-56
57. Khan IU, Beck-Sickinger AG. Targeted tumor diagnosis and therapy with peptide hormones as radiopharmaceuticals. Anticancer Agents Med Chem 2008;8:186-199
58. García-Garayoa E, Allemann-Tannahill L, Bläuenstein P, et al. In vitro. and in vivo evaluation of new radiolabeled neurotensin(8-13) analogues with high affinity for NT1 receptors. Nucl Med Biol 2001;28:75-84
59. Hillairet De Boisferon M, Raguin O, Thiercelin C, et al. Improved tumor selectivity of radiolabeled peptides by receptor and antigen dual targeting in the neurotensin receptor model. Bioconjug Chem 2002;13:654-662 (Pubitemid 34527529)
60. Achilefu S, Srinivasan A, Schmidt MA, et al. Novel bioactive and stable neurotensin peptide analogues capable of delivering radiopharmaceuticals and molecular beacons to tumors. J Med Chem 2003;46:3403-3411 (Pubitemid 36842424)
61. 18F-labeled neurotensin(8-13) analogs. Nucl Med Biol 2002;29:61-72
62. 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer. Eur J Nucl Med Mol Imaging 2003;30:1134-1139
63. Reubi JC, Waser B, Friess H, et al. Neurotensin receptors: a new marker for human ductal pancreatic adenocarcinoma. Gut 1998;42:546-550 (Pubitemid 28186573)
64. Lundquist JT 4th, Dix TA. Preparation and receptor binding affinities of cyclic C-terminal neurotensin (8-13) and (9-13) analogues. Bioorg Med Chem Lett 1999;9:2579-2582
65. Hong F, Zaidi J, Cusack B, et al. Synthesis and biological studies of novel neurotensin(8-13) mimetics. Bioorg Med Chem 2002;10:3849-3858
66. Falciani C, Fabbrini M, Pini A, et al. Synthesis and biological activity of stable branched neurotensin peptides for tumor targeting. Mol Cancer Ther 2007;6:2441-2448 (Pubitemid 47480409)
67. Kokko KP, Hadden MK, Orwig KS, et al. In vitro analysis of stable, receptor-selective neurotensin[8-13] analogues. J Med Chem 2003;46:4141-4148
68. 99mTc-NT-XI, evaluated in ductal pancreatic adenocarcinoma patients. J Nucl Med 2003;44:1649-1654